Wavelength Pharmaceuticals
Edit

Wavelength Pharmaceuticals

https://www.wavelengthpharma.com/
Last activity: 16.08.2021
Active
Categories: ActiveCommerceIndustryInformationITManufacturingMedtechProductServiceSupply
כחברה הרואה בעצמה תומכת אסטרטגית ושותפה לדרך של לקוחותיה, אנו מציעים מגוון רחב של פתרונות ייצור API המותאמים לצרכיהם באופן המדויק ביותר.
ההתפתחות המתמדת, השימוש בטכנולוגיה החדשנית והמובילה בשוק והעמידה הבלתי מתפשרת בכל תקני
ה-GMP המחמירים ביותר הם נר לרגלינו, והם המאפשרים לנו למצב את לקוחותינו בחוד החנית של התעשייה הפרמצבטית העולמית.

אנו ב- Wavelength מאמינים בגיוון אנושי, בעבודת צוות אמיתית ופתוחה וביכולת ההשפעה המשמעותית של כל עובד ומתגאים בצוות המקצועי והמיומן שלנו, בגמישות והיכולת לעבוד בהרמוניה באופן היעיל והפרודוקטיבי ביותר. השאיפה למצוינות ואיכות מקסימלית בכל נדבך של עשייה, מאפשרת לנו להמשיך ולהיות חברה בינלאומית מובילה בתחום ה-API.
Likes
1.02K
Mentions
17
Location: Israel, South District, Beer Sheva
Employees: 201-500
Phone: +972 8-650-9111
Founded date: 1987
Facebook
LinkedIn
Youtube
Email

Investors 1

Mentions in press and media 17

DateTitleDescription
16.08.2021Tikun olam-Cannbit continues to expand its footprint in the pharmaceutical arenaTEL AVIV, Israel, Aug. 16, 2021 /PRNewswire/ -- Tikun-Olam Cannbit (TASE:TKUN) reported the first and exclusive partnership of its kind with Wavelength, an Israeli company that develops, manufactures, and exports active pharmaceutical ingre...
18.02.2021Roy­al­ty Phar­ma gets more com­pe­ti­tion as a pri­vate eq­ui­ty firm launch­es $725M roy­al­ty-buy­ing fundJust a couple of weeks after Bristol Myers Squibb finally won an FDA OK for liso-cel, investigators at Penn posted a 5-year update on a small group of patients suffering from non-Hodgkin lymphoma who were treated with Novartis’ pioneering C...
18.02.2021Amid the 'su­per­bug' cri­sis, a Big Phar­ma-backed fund scores a mea­ger raise for an­tibi­otics R&D. Is $140M near­ly enough?Years af­ter Big Phar­ma aban­doned the an­tibi­otics space, a small syn­di­cate has raised $140 mil­lion to ad­dress the loom­ing threat of an­timi­cro­bial re­sis­tance — but is it too lit­tle, too late? Back in Ju­ly, more than 20 biotec...
18.02.2021Is­raeli API mak­er Wave­length buys up ma­jor­i­ty stake in In­di­an firm mak­ing drug start­ing ma­te­ri­als and in­ter­me­di­atesWith the cell and gene therapy space as hot as ever, big-name CDMO Charles River Laboratories is looking to carve out a big piece of the pie. To get there, it’s snapping up a Memphis-based specialist in the space. Charles River Laboratories...
18.02.2021Roy­al­ty Phar­ma gets more com­pe­ti­tion as a pri­vate eq­ui­ty firm launch­es $725M roy­al­ty-buy­ing fundGlenn Rockman was summoned, about three years into a senior role on JP Morgan’s non-profit investment banking team, to a special assignment reviewing a pipeline of drugs, vaccines and diagnostics for neglected diseases the Bill & Melind...
18.02.2021Is­raeli API mak­er Wave­length buys up ma­jor­i­ty stake in In­di­an firm mak­ing drug start­ing ma­te­ri­als and in­ter­me­di­atesAfter a blistering start to 2021, it seemed as though news in the biotech manufacturing world had slowed to a more reasonable pace in the last few weeks. Then the news came down Wednesday of an expensive merger in one of the fastest-growing...
18.02.2021Roy­al­ty Phar­ma gets more com­pe­ti­tion as a pri­vate eq­ui­ty firm launch­es $725M roy­al­ty-buy­ing fundPablo’s got some peers. Twen­ty-five years af­ter Mex­i­can bil­lion­aire Pablo Legor­re­ta start­ed buy­ing up fu­ture roy­al­ties on ap­proved drugs — and eight months af­ter he turned that in­to a record-set­ting $2.2 bil­lion IPO for Ro...
18.02.2021Covid-19 roundup: South African vari­ant trips up Pfiz­er/BioN­Tech, Mod­er­na vac­cines while EU seeks an­ti-vari­ant con­tract claus­es — re­portAs ques­tions con­tin­ue to swirl about the ef­fec­tive­ness of cur­rent vac­cines against new vari­ants of the coro­n­avirus, a pair of let­ters to the ed­i­tor con­firm that those de­vel­oped by Pfiz­er/BioN­Tech and Mod­er­na ap­pear to ...
18.02.2021Ed­uar­do Bra­vo re­turns to bring Eu­ro­pean biotech in on the SPAC splurgeThe last year’s SPAC boom has been dom­i­nat­ed so far by US-based VCs. Now a promi­nent Eu­ro­pean biotech ex­ec­u­tive and a cou­ple in­vestors are get­ting in on the game. Ed­uar­do Bra­vo, the Big Phar­ma alum and for­mer CEO of the cel...
18.02.2021Proven­tion Bio inks Chi­na deal for au­toim­mune pro­gram; Ky­owa Kirin re­leas­es pos­i­tive topline da­ta in atopic der­mati­tisProven­tion Bio is mak­ing its way in­to Chi­na with a new deal an­nounced Wednes­day. The Red Bank, NJ-based biotech has agreed to a deal with a sub­sidiary of Huadong Med­i­cine to work on PRV-3279, a bis­pe­cif­ic an­ti­body-based mol­e­...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In